Matthew Siegel is vice president of medical affairs at Maine Behavioral Healthcare in Portland.
Matthew Siegel
Vice president
Maine Behavioral Healthcare
From this contributor
Autism can mask anxiety symptoms
Anxiety is one of the most common mental health conditions, as well as one of the most treatable. But when a person has autism, anxiety symptoms can be hard to see. Matthew Siegel calls for anxiety tests and treatments that are tailored to people with autism.
Searching for psychiatrists with expertise in autism
There is an urgent need for psychiatrists who are trained to care for individuals with autism. Matthew Siegel calls for a formal training program in autism for psychiatrists.
Searching for psychiatrists with expertise in autism
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.